María E Rodriguez-Ruiz1, Saray Garasa2, Inmaculada Rodriguez2, Jose Luis Solorzano3, Benigno Barbes3, Alba Yanguas4, Alvaro Teijeira2, Iñaki Etxeberria2, José Javier Aristu3, Cornelia Halin5, Ignacio Melero6, Ana Rouzaut4. 1. Division of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Pamplona, Spain; Radiation Oncology, University Clinic, University of Navarra, Pamplona, Spain. Electronic address: mrruiz@unav.es. 2. Division of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Pamplona, Spain. 3. Radiation Oncology, University Clinic, University of Navarra, Pamplona, Spain. 4. Division of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Pamplona, Spain; Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain. 5. Pharmaceutical Immunology, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland. 6. Division of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Pamplona, Spain; Radiation Oncology, University Clinic, University of Navarra, Pamplona, Spain.
Abstract
PURPOSE/ OBJECTIVES: The goal of this study was to assess the effects of ionizing radiation on the expression of the integrin ligands ICAM-1 and VCAM that control leucocyte transit by lymphatic endothelial cells. MATERIALS/ METHODS: Confluent monolayers of primary human lymphatic endothelial cells (LEC) were irradiated with single dose of 2, 5, 10 or 20 Gy, with 6 MeV-x-rays using a Linear-Accelerator. ICAM-1 and VCAM expression was determined by flow cytometry. Human tissue specimens received a single dose of 20 Gy with 15 MeV-x-rays. MC38, B16-OVA or B16-VEGF-C tumors grown in C57BL/6 mice were irradiated with single dose of 20Gy using a Linear-Accelerator fitted with a 10mm Radiosurgery collimator. Clinical samples were obtained from patients previous and 4 weeks after complete standard radiotherapy. ICAM-1 and VCAM expression was detected in all tissue specimens by confocal microscopy. To understand the role of TGFβ in this process anti-TGFβ blocking mAb were injected i.p. 30min before radiotherapy. Cell adhesion to irradiated LEC was analyzed in adhesion experiments performed in the presence or in the absence of anti- TGFβ and /or anti-ICAM1 blocking mAb. RESULTS: We demonstrate that lymphatic endothelial cells in tumor samples experience induction of surface ICAM-1 and VCAM when exposed to ionizing radiation in a dose- and time-dependent manner. These effects can be recapitulated in cultured LEC, and are in part mediated by TGFβ. These data are consistent with increases in ICAM-1 and VCAM expression on LYVE-1+ endothelial cells in freshly explanted human tumor tissue and in mouse transplanted tumors after radiotherapy. Finally, ICAM-1 and VCAM expression accounts for enhanced adherence of human T lymphocytes to irradiated LEC. CONCLUSION: Our results show induction of ICAM-1 and VCAM on LVs in irradiated lesions and offer a starting point for elucidating the biological and therapeutic implications of targeting leukocyte traffic in combination to immunotherapy.
PURPOSE/ OBJECTIVES: The goal of this study was to assess the effects of ionizing radiation on the expression of the integrin ligands ICAM-1 and VCAM that control leucocyte transit by lymphatic endothelial cells. MATERIALS/ METHODS: Confluent monolayers of primary human lymphatic endothelial cells (LEC) were irradiated with single dose of 2, 5, 10 or 20 Gy, with 6 MeV-x-rays using a Linear-Accelerator. ICAM-1 and VCAM expression was determined by flow cytometry. Human tissue specimens received a single dose of 20 Gy with 15 MeV-x-rays. MC38, B16-OVA or B16-VEGF-Ctumors grown in C57BL/6 mice were irradiated with single dose of 20Gy using a Linear-Accelerator fitted with a 10mm Radiosurgery collimator. Clinical samples were obtained from patients previous and 4 weeks after complete standard radiotherapy. ICAM-1 and VCAM expression was detected in all tissue specimens by confocal microscopy. To understand the role of TGFβ in this process anti-TGFβ blocking mAb were injected i.p. 30min before radiotherapy. Cell adhesion to irradiated LEC was analyzed in adhesion experiments performed in the presence or in the absence of anti- TGFβ and /or anti-ICAM1 blocking mAb. RESULTS: We demonstrate that lymphatic endothelial cells in tumor samples experience induction of surface ICAM-1 and VCAM when exposed to ionizing radiation in a dose- and time-dependent manner. These effects can be recapitulated in cultured LEC, and are in part mediated by TGFβ. These data are consistent with increases in ICAM-1 and VCAM expression on LYVE-1+ endothelial cells in freshly explanted humantumor tissue and in mouse transplanted tumors after radiotherapy. Finally, ICAM-1 and VCAM expression accounts for enhanced adherence of human T lymphocytes to irradiated LEC. CONCLUSION: Our results show induction of ICAM-1 and VCAM on LVs in irradiated lesions and offer a starting point for elucidating the biological and therapeutic implications of targeting leukocyte traffic in combination to immunotherapy.
Authors: M Protopapa; V Kouloulias; A Kougioumtzopoulou; Z Liakouli; C Papadimitriou; A Zygogianni Journal: Clin Transl Oncol Date: 2019-06-28 Impact factor: 3.405
Authors: Ravi B Patel; Claire C Baniel; Raghava N Sriramaneni; Kristin Bradley; Stephanie Markovina; Zachary S Morris Journal: Brachytherapy Date: 2018-08-02 Impact factor: 2.362
Authors: Justin C Jagodinsky; Gabriella Medeiros; Hayley H Raj; Amira Razuan; Alexis Locsin; Tirhas G Dempsey; Beixiao Tang; Ishan Chakravarty; Paul A Clark; Raghava N Sriramaneni; Won Jong Jin; Keng-Hsueh Lan; Rupak K Das; Jessica R Miller; Darilis Suarez-Gonzalez; Zachary S Morris Journal: Brachytherapy Date: 2021-03-27 Impact factor: 2.441
Authors: Thomas Walle; Rafael Martinez Monge; Adelheid Cerwenka; Daniel Ajona; Ignacio Melero; Fernando Lecanda Journal: Ther Adv Med Oncol Date: 2018-01-18 Impact factor: 8.168